Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report)'s share price was down 5.5% on Tuesday . The company traded as low as $0.58 and last traded at $0.58. Approximately 795,381 shares changed hands during trading, a decline of 36% from the average daily volume of 1,235,559 shares. The stock had previously closed at $0.62.
Elite Pharmaceuticals Stock Down 5.3%
The firm has a 50 day moving average of $0.57 and a two-hundred day moving average of $0.51. The company has a quick ratio of 3.50, a current ratio of 4.88 and a debt-to-equity ratio of 0.08.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last released its quarterly earnings data on Monday, June 30th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. The firm had revenue of $32.00 million during the quarter. Elite Pharmaceuticals had a positive return on equity of 3.96% and a negative net margin of 5.13%.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
